Publications by authors named "John Springer"

Claim this Profile
A
Aminopyrazole Carboxamide Bruton's Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning.
Mark E Schnute, Stephen E Benoit, Ingrid P Buchler, Nicole Caspers, Margaret L Grapperhaus, John R Springer

ACS Med Chem Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A survey of scholarly literature describing the field of bioinformatics education and bioinformatics educational research.
Alejandra J Magana, Manaz Taleyarkhan, Daniela Rivera Alvarado, Michael Kane, John Springer

CBE Life Sci Educ· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Construction of a drug safety assurance information system based on clinical genotyping.
John A Springer, Nicholas V Iannotti, Jon E Sprague, Michael D Kane

ISRN Bioinform· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
Graciela B Arhancet, Daniel P Walker, Sue Metz, Yvette M Fobian, Steven E Heasley, John R Springer

Bioorg Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: use of a conformation-based hypothesis to facilitate compound design.
Daniel P Walker, Graciela B Arhancet, Hwang-Fun Lu, Steven E Heasley, Sue Metz, John R Springer

Bioorg Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomics training using an instructional software system.
John A Springer, Nicholas V Iannotti, Michael D Kane, Kevin Haynes, Jon E Sprague

Am J Pharm Educ· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life.
Jane L Wang, David Limburg, Matthew J Graneto, John Springer, Joseph Rogier Bruce Hamper

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug safety assurance through clinical genotyping: near-term considerations for a system-wide implementation of personalized medicine.
Michael D Kane, John A Springer, Jon E Sprague

Per Med· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis